2025 American Society of Clinical Oncology Annual Meeting
The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting will feature key research and treatment updates in thoracic oncology. The annual meeting provides opportunities to “discover state-of-the-art research, groundbreaking treatments, and visionary insights that will ignite your passion for oncology,” organizers said. The 2025 ASCO Annual Meeting is taking place May 30 to June 3, 2025, in Chicago, Illinois.
Dr. Osarogiagbon discussed the impact of the lung cancer screening program on diagnosis rates across the Mississippi Delta.
In the second segment of this interview, Feldman discussed the importance of patient advocacy in clinical trial research.
Thorsten Füreder, MD, shares insights from the NSCLC cohort of the phase 2 trial.
Dr. Liu explains how these two studies are shaping standards of care and the treatment landscape in SCLC.
The phase 3 study compared the efficacy data of benmelstobart plus anlotinib with that of pembrolizumab monotherapy.
Dr. Culver discusses the organization's work at ASCO and the importance of having a patient advocacy presence at the meeting.
The results of the interim analysis comparing safety and efficacy were presented at the 2025 ASCO Annual Meeting.
Xiuning Le, MD, PhD, discusses the phase 3 trial, which follows the SOHO-01 trial of the oral TKI.
Researchers compared sacituzumab tirumotecan, a TROP2-directed antibody drug conjugate, with platinum-based chemotherapy.
Other analyses suggest that lack of ctDNA clearance with neoadjuvant therapy or with MRD postsurgery leads to worse outcomes.
The study investigated HER3-DXd in patients with advanced EGFRm NSCLC after progression during treatment with an EGFR TKI.
Learn more about outcomes from the first minimal residual disease analysis of the DART trial.
Dr. Archambault discusses the safety and effectiveness of cemiplimab plus chemotherapy for first-line treatment of aNSCLC.
Dr. Conkling shared his research insights on PD-L1 testing practices for mNSCLC within US community oncology settings.
Dr. Osarogiagbon shared insights on findings from the incidental lung nodule program and lung cancer screening program.
Jessica Bauman, MD, discusses a new analysis of the REACH PC study that she presented at ASCO 2025.
Dr. Liu weighs in on the CheckMate 816 data presented at the 2025 ASCO Annual Meeting.
Jorge Nieva, MD, discusses a recent study that evaluated the impact of circadian rhythms on the efficacy of immunotherapy.
Dr. Sen explains how her team identified targetable genes that define immune suppression in small cell lung cancer.
Jennifer Carlisle, MD, shares her institution’s experience with outpatient administration of the bispecific T-cell ...
Coral Olazagasti, MD, reflects on ASCO 2025 updates and the importance of bringing this news back to patients in the clinic.
Local therapy is recommended by NCCN guidelines, but how it is used in oligoprogressive disease is not well described.
Cheryl Czerlanis, MD, shares insights from her ASCO 2025 presentation on the topic.
The study participants include those who have had at least one first-degree relative diagnosed with lung cancer.
Sophie Poznanski, PhD, shares insights from her ASCO 2025 presentation on the multifunctional antibody modality.
The study compared results from North America with global results by high-income and low- or middle-income countries.
Mariano Provencio, MD, PhD, presented the results of CheckMate 77T as a late-breaking abstract at ASCO 2025.
Cheryl Czerlanis, MD, shares insights from the session on lung cancer screening that she chaired at ASCO 2025.
Phase 2 of the study investigated the targeted therapy in treatment-naive patients with stage III ALK-positive disease.
Patrick M. Forde, MD, presented the late-breaking abstract during an oral abstract session at the 2025 ASCO Annual Meeting.
Palliative care researchers discuss differences in lung cancer treatment disparities across Hispanic patient subgroups.
Helena Yu, MD, discusses research updates from REZILIENT1 that were presented at ASCO 2025.
Coral Olazagasti, MD, and Maria Velez, MD, MS, reflect on the opportunities at the ASCO Annual Meeting.
Phase 3 DeLLphi-304 Trial Shows Tarlatamab Significantly Improves OS, PFS in Previously Treated SCLC
Charles Rudin, MD, PhD, presented the data at the 2025 American Society of Clinical Oncology Annual Meeting.
The study compared treatment with neoadjuvant osimertinib with or without chemotherapy versus chemotherapy alone.
Jennifer Carlisle, MD, discusses amivantamab, and the multidimensional impact of toxicity management at ASCO 2025.
Researchers tested Dato-DXd for safety and tolerability in patients with advanced NSCLC.
Efficacy results, safety data, and survival data from the phase 2 study were presented at the ASCO 2025 Annual Meeting.
Coral Olazagasti, MD, shares why the ASCO Annual Meeting is a critical time to bring the field together.
Dr. Singhi unpacks the thoracic oncology data and highlights coming up at this year's ASCO Annual Meeting.
Stephen V. Liu, MD, shares what he sees as the key upcoming highlights in thoracic oncology at the ASCO Annual Meeting.
Lurbinectedin plus atezolizumab demonstrated a “clinically meaningful benefit” in patients with ES-SCLC.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.